

## Highlights of This Issue 1621

## SPECIAL FEATURES

## CCR Drug Updates

- 1623** Nivolumab in the Treatment of Hodgkin Lymphoma  
Stephen M. Ansell

## CCR Focus

- 1628** Pancreatic Cancer: Challenge and Inspiration  
Susan E. Bates
- 1629** Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma"  
Erkut Borazanci, Chi V. Dang, Robert W. Robey, Susan E. Bates, John A. Chabot, and Daniel D. Von Hoff
- 1638** Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development  
Stephan B. Dreyer, David K. Chang, Peter Bailey, and Andrew V. Biankin
- 1647** Re-engineering the Pancreas Tumor Microenvironment: A "Regenerative Program" Hacked  
Gerard I. Evan, Nasun Hah, Trevor D. Littlewood, Nicole M. Sodir, Tania Campos, Michael Downes, and Ronald M. Evans
- 1656** Strategies for Increasing Pancreatic Tumor Immunogenicity  
Burles A. Johnson III, Mark Yarchoan, Valerie Lee, Daniel A. Laheru, and Elizabeth M. Jaffee
- 1670** Current and Emerging Therapies in Metastatic Pancreatic Cancer  
Gulam Abbas Manji, Kenneth P. Olive, Yvonne M. Saenger, and Paul Oberstein

## CANCER THERAPY: CLINICAL

- 1679** Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study  
Annemieke J.M. Nieuweboer, Anne-Joy M. de Graan, Paul Hamberg, Sander Bins, Robert J. van Soest, Robbert J. van Alphen, Andries M. Bergman, Aart Beeker, Henk van Halteren, Albert J. ten Tije, Hanneke Zuetenhorst, Nelly van der Meer, Dana Chitu, Ronald de Wit, and Ron H.J. Mathijssen, on behalf of the Dutch Uro-Oncology Studygroup (DUOS)
- 1684** Oral Bisphosphonates and Improved Survival of Breast Cancer  
Gad Rennert, Mila Pinchev, Naomi Gronich, Walid Saliba, Anath Flugelman, Idit Lavi, Hadassah Goldberg, Georgeta Fried, Mariana Steiner, Arie Bitterman, Keren Landsman, and Hedy S. Rennert
- 1690** Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment  
Ming-Lung Yu, Chung-Feng Huang, Ming-Lun Yeh, Pei-Chien Tsai, Ching-I. Huang, Meng-Hsuan Hsieh, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, and Wan-Long Chuang

## PERSONALIZED MEDICINE AND IMAGING

- 1698** Signal Transduction and Activator of Transcription-3 (STAT3) in Patients with Colorectal Cancer: Associations with the Phenotypic Features of the Tumor and Host  
James H. Park, Hester van Wyk, Donald C. McMillan, Jean Quinn, Jennifer Clark, Campbell S.D. Roxburgh, Paul G. Horgan, and Joanne Edwards
- 1710** Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen  
Heather M. Brechbuhl, Jessica Finlay-Schultz, Tomomi M. Yamamoto, Austin E. Gillen, Diana M. Citty, Aik-Choon Tan, Sharon B. Sams, Manoj M. Pillai, Anthony D. Elias, William A. Robinson, Carol A. Sartorius, and Peter Kabos

# Table of Contents

- 1722** Paired High-Content Analysis of Prostate Cancer Cells in Bone Marrow and Blood Characterizes Increased Androgen Receptor Expression in Tumor Cell Clusters



Anders Carlsson, Peter Kuhn, Madelyn S. Luttgen, Kevin K. Dizon, Patricia Troncoso, Paul G. Corn, Anand Kolatkar, James B. Hicks, Christopher J. Logothetis, and Amado J. Zurita

## CANCER THERAPY: PRECLINICAL

- 1733** The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway

Katia Beider, Evgenia Rosenberg, Hanna Bitner, Avichai Shimoni, Merav Leiba, Maya Koren-Michowitz, Elena Ribakovskiy, Shiri Klein, Devorah Olam, Lola Weiss, Hanna Wald, Michal Abraham, Eithan Galun, Amnon Peled, and Arnon Nagler

- 1748** Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma



Daoxiang Zhang, Lin Li, Hongmei Jiang, Brett L. Knolhoff, Albert C. Lockhart, Andrea Wang-Gillam, David G. DeNardo, Marianna B. Ruzinova, and Kian-Huat Lim

- 1760** Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—



Mechanism and Monitoring  
Magali Guffroy, Hadi Falahatpisheh, Kathleen Biddle, John Kreeger, Leslie Obert, Karen Walters, Richard Goldstein, Germaine Boucher, Timothy Coskran, William Reagan, Danielle Sullivan, Chunli Huang, Sharon Sokolowski, Richard Giovanelli, Hans-Peter Gerber, Martin Finkelstein, and Nasir Khan

- 1771** Inhibition of *STAT3* with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity

Seiichi Odate, Veronica Veschi, Shuang Yan, Norris Lam, Richard Woessner, and Carol J. Thiele

- 1785** Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

Lori S. Hart, JulieAnn Rader, Pichai Raman, Vandana Batra, Mike R. Russell, Matthew Tsang, Maria Gagliardi, Lucy Chen, Daniel Martinez, Yimei Li, Andrew Wood, Sunkyu Kim, Sudha Parasuraman, Scott Delach, Kristina A. Cole, Shiva Krupa, Markus Boehm, Malte Peters, Giordano Caponigro, and John M. Maris

- 1797** Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression

Heather Nesbitt, Niall M. Byrne, S. Nicole Williams, Louise Ming, Jenny Worthington, Rachel J. Errington, Laurence H. Patterson, Paul J. Smith, Stephanie R. McKeown, and Declan J. McKenna

- 1809** BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection—Implications for Oncolytic Viral Therapy

Chelsea Bolyard, W. Hans Meisen, Yeshavanth Banasavadi-Siddegowda, Jayson Hardcastle, Ji Young Yoo, Eric S. Wohleb, Jeffrey Wojton, Jun-Ge Yu, Samuel Dubin, Maninder Khosla, Bo Xu, Jonathan Smith, Christopher Alvarez-Breckenridge, Pete Pow-anpongkul, Flavia Pichiorri, Jianying Zhang, Matthew Old, Dan Zhu, Erwin G. Van Meir, Jonathan P. Godbout, Michael A. Caligiuri, Jianhua Yu, and Balveen Kaur

## BIOLOGY OF HUMAN TUMORS

- 1820** The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma



Colm Keane, Clare Gould, Kimberley Jones, David Hamm, Dipti Talaulikar, Jonathan Ellis, Frank Vari, Simone Birch, Erica Han, Peter Wood, Kim-Anh Le-Cao, Michael R. Green, Pauline Crooks, Sanjiv Jain, Josh Tobin, Raymond J. Steptoe, and Maher K. Gandhi

- 1829** Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer

Johannes Brägelmann, Niklas Klümper, Anne Offermann, Anne von Mässenhausen, Diana Böhm, Mario Deng, Angela Queisser, Christine Sanders, Isabella Syring, Axel S. Merseburger, Wenzel Vogel, Elisabeth Sievers, Ignacija Vlastic, Jessica Carlsson, Ove Andrén, Peter Brossart, Stefan Duensing, Maria A. Svensson, Zaki Shaikhibrahim, Jutta Kirfel, and Sven Perner

- 1841** Landscape of Genomic Alterations in Pituitary Adenomas

Wenya Linda Bi, Peleg Horowitz, Noah F. Greenwald, Malak Abedalthagafi, Pankaj K. Agarwalla, William J. Gibson, Yu Mei, Steven E. Schumacher, Uri Ben-David, Aaron Chevalier, Scott Carter, Grace Tiao, Priscilla K. Brastianos, Azra H. Ligon, Matthew Ducar, Laura MacConaill, Edward R. Laws Jr, Sandro Santagata, Rameen Beroukhi, and Ian F. Dunn

# Table of Contents

## 1852 Somatic and Germline *TP53* Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors

Amy L. Sherborne, Vincent Lavergne, Katharine Yu, Leah Lee, Philip R. Davidson, Tali Mazor, Ivan V. Smirnov, Andrew E. Horvai, Mignon Loh, Steven G. DuBois, Robert E. Goldsby, Joseph P. Neglia, Sue Hammond, Leslie L. Robison, Rosanna Wustrack, Joseph F. Costello, Alice O. Nakamura, Kevin M. Shannon, Smita Bhatia, and Jean L. Nakamura

## 1862 Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition



George Au-Yeung, Franziska Lang, Walid J. Azar, Chris Mitchell, Kate E. Jarman, Kurt Lackovic, Diar Aziz, Carleen Cullinane, Richard B. Pearson, Linda Mileschkin, Danny Rischin, Alison M. Karst, Ronny Drapkin, Dariush Etemadmoghadam, and David D.L. Bowtell

## CORRECTION


## 1875 Correction: ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy

 AC icon indicates Author Choice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)

## ABOUT THE COVER

Estrogen receptor expression and response to antiendocrine therapy in luminal breast cancer are dependent on fibroblast subtypes present in the tumor microenvironment. The cover shows strong estrogen receptor alpha staining (red) in luminal breast cancer cells (green) supported by the presence of CD146pos fibroblasts. For details, see the article by Brechbuhl and colleagues on page 1710 of this issue.



# Clinical Cancer Research

**23 (7)**

*Clin Cancer Res* 2017;23:1621-1876.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/23/7>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/23/7>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.